1
|
McIntosh LA, Burns JD, Tereshatov EE, Muzzioli R, Hagel K, Jinadu NA, McCann LA, Picayo GA, Pisaneschi F, Piwnica-Worms D, Schultz SJ, Tabacaru GC, Abbott A, Green B, Hankins T, Hannaman A, Harvey B, Lofton K, Rider R, Sorensen M, Tabacaru A, Tobin Z, Yennello SJ. Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply. Nucl Med Biol 2023; 126-127:108387. [PMID: 37837782 DOI: 10.1016/j.nucmedbio.2023.108387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 09/04/2023] [Accepted: 09/18/2023] [Indexed: 10/16/2023]
Abstract
The alpha emitter astatine-211 (211At) is a promising candidate for cancer treatment based on Targeted Alpha (α) Therapy (TAT). A small number of facilities, distributed across the United States, are capable of accelerating α-particle beams to produce 211At. However, challenges remain regarding strategic methods for shipping 211At in a form adaptable to advanced radiochemistry reactions and other uses of the radioisotope. PURPOSE Our method allows shipment of 211At in various quantities in a form convenient for further radiochemistry. PROCEDURES For this study, a 3-octanone impregnated Amberchrom CG300M resin bed in a column cartridge was used to separate 211At from the bismuth matrix on site at the production accelerator (Texas A&M) in preparation for shipping. Aliquots of 6 M HNO3 containing up to ≈2.22 GBq of 211At from the dissolved target were successfully loaded and retained on columns. Exempt packages (<370 MBq) were shipped to a destination radiochemistry facility, University of Texas MD Anderson Cancer Center, in the form of a convenient air-dried column. Type A packages have been shipped overnight to University of Alabama at Birmingham. MAIN FINDINGS Air-dried column hold times of various lengths did not inhibit simple and efficient recovery of 211At. Solution eluted from the column was sufficiently high in specific activity to successfully radiolabel a model compound, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1), with 211At. The method to prepare and ship 211At described in this manuscript has also been used to ship larger quantities of 211At a greater distance to University of Alabama at Birmingham. PRINCIPAL CONCLUSIONS The successful proof of this method paves the way for the distribution of 211At from Texas A&M University to research institutions and clinical oncology centers in Texas and elsewhere. Use of this simple method at other facilities has the potential increase the overall availability of 211At for preclinical and clinical studies.
Collapse
Affiliation(s)
- Lauren A McIntosh
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA.
| | - Jonathan D Burns
- Chemistry Department, The University of Alabama at Birmingham, Birmingham, AL 35924, USA.
| | | | - Riccardo Muzzioli
- Department of Cancer System Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Kris Hagel
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA
| | - Noimat A Jinadu
- Chemistry Department, The University of Alabama at Birmingham, Birmingham, AL 35924, USA
| | - Laura A McCann
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Gabriela A Picayo
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Federica Pisaneschi
- Department of Cancer System Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) at The University of Texas Health Science Center at Houston, USA
| | - David Piwnica-Worms
- Department of Cancer System Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Steven J Schultz
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Gabriel C Tabacaru
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA
| | - Austin Abbott
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Brooklyn Green
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Travis Hankins
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Andrew Hannaman
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Bryan Harvey
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Physics Department, Texas A&M University, College Station, TX 77843, USA
| | - Kylie Lofton
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Robert Rider
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Maxwell Sorensen
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Alexandra Tabacaru
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA
| | - Zachary Tobin
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Sherry J Yennello
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| |
Collapse
|
2
|
Albertsson P, Bäck T, Bergmark K, Hallqvist A, Johansson M, Aneheim E, Lindegren S, Timperanza C, Smerud K, Palm S. Astatine-211 based radionuclide therapy: Current clinical trial landscape. Front Med (Lausanne) 2023; 9:1076210. [PMID: 36687417 PMCID: PMC9859440 DOI: 10.3389/fmed.2022.1076210] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 12/06/2022] [Indexed: 01/09/2023] Open
Abstract
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
Collapse
Affiliation(s)
- Per Albertsson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,*Correspondence: Per Albertsson ✉
| | - Tom Bäck
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Karin Bergmark
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Andreas Hallqvist
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Mia Johansson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Emma Aneheim
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Sture Lindegren
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Chiara Timperanza
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Knut Smerud
- Smerud Medical Research International AS, Oslo, Norway
| | - Stig Palm
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
3
|
Qaim SM, Spahn I, Scholten B, Spellerberg S, Neumaier B. The role of chemistry in accelerator-based production and separation of radionuclides as basis for radiolabelled compounds for medical applications. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Radiochemical separations used in large scale routine production of diagnostic and therapeutic radionuclides at a particle accelerator for patient care are briefly outlined. The role of chemistry at various stages of development of a production route of a novel radionuclide, namely nuclear data measurement, high-current targetry, chemical processing and quality control of the product, is discussed in detail. Special attention is paid to production of non-standard positron emitters (e.g. 44gSc, 64Cu, 68Ga, etc.) at a cyclotron and novel therapeutic radionuclides (e.g. 67Cu, 225Ac, etc.) at an accelerator. Some typical examples of radiochemical methods involved are presented.
Collapse
Affiliation(s)
- Syed M. Qaim
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Bernhard Scholten
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Stefan Spellerberg
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| |
Collapse
|